A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SUSTAIN
- Sponsors Biogen
- 19 May 2017 Status changed from not yet recruiting to recruiting.
- 17 Apr 2017 Planned initiation date changed from 1 Dec 2016 to 18 Apr 2017.
- 17 Apr 2017 Status changed from recruiting to not yet recruiting.